Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's ...

Several KOLs have highlighted concerns over cost with Symbravo, since fixed-dose combination (FDC) drugs tend to be expensive ...

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for ...

Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.

Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

CHICAGO, April 20, 2026 /PRNewswire/ -- Experts from NYU Langone Health's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology ...

CAR-T therapy delivered significant clinical improvements in adults with stiff person syndrome (SPS) in the pivotal ...

Please provide your email address to receive an email when new articles are posted on . Patients should always engage in thorough discussions with their neurologist before attempting any treatment.

ULIXACALTAMIDE maintained response in essential tremor in a Phase III randomized withdrawal study at AAN 2026. The topline ...

A newly released position statement from the American Academy of Neurology (AAN) provides guidance to neurologists about counseling patients with Alzheimer's disease (AD) and their families about the ...